Precigen announces clearance of ind to initiate phase 1/1b study for prgn-3007 ultracar-t® in advanced ror1+ hematological and solid tumors

Germantown, md., oct. 26, 2021 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the us food and drug administration (fda) has cleared the investigational new drug (ind) application to initiate the phase 1/1b clinical trial of prgn-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ror1+) hematological and solid tumors.
PGEN Ratings Summary
PGEN Quant Ranking